---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-023162"
form_type: "8-K"
ticker: "CATX"
cik: "0000728387"
company_name: "Perspective Therapeutics, Inc."
filed_at: "2023-08-11T23:59:59+00:00"
generated_at: "2026-06-11T15:53:22.594473+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Perspective Q2 net loss widens to $11.1M on 17% revenue drop; pipeline advances

## Summary
- Q2 2023 revenue $2.1M (-17% YoY); net loss $11.1M vs $2.1M loss a year ago.
- Cash and equivalents $28.5M at June 30, 2023, down from $43.9M at Dec 31, 2022.
- Phase 1/2a trials initiated for VMT-α-NET (neuroendocrine) and VMT01 (melanoma); first patient dosed; preliminary data expected by end-2023.
- New executives: Heidi Henson (Audit Chair), Andrew Bright (EVP Brachytherapy), Shane Cobb (EVP Operations).
- Cesium-131 brachytherapy data showed 96% disease-free survival at 10 years for prostate cancer.

## SEC filing metadata
- accession: 0001437749-23-023162
- form_type: 8-K
- ticker: CATX
- cik: 0000728387
- company_name: Perspective Therapeutics, Inc.
- filed_at: 2023-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/728387/000143774923023162/0001437749-23-023162-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/728387/000143774923023162/isr20230809_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-023162
- JSON: https://secwatch.observer/filing/0001437749-23-023162.json
- Plain text: https://secwatch.observer/filing/0001437749-23-023162.txt

## Key facts
- Earnings Releases
  Perspective Therapeutics, Inc. reported financial results for second quarter of fiscal 2023 ended June 30, 2023.
  - Period: second quarter of fiscal 2023 ended June 30, 2023
  - Result: reported results
  source text: On August 11, 2023, the Company issued a press release announcing its financial results for the second quarter of fiscal 2023 ended June 30, 2023, the text of which is attached hereto as Exhibit 99.1.
  evidence_url: https://www.sec.gov/Archives/edgar/data/728387/000143774923023162/0001437749-23-023162-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.